Hims & Hers Health, Inc. (NYSE:HIMS) shares rose more than 19% since the company’s reported Q4 results on Monday, with EPS of ($0.05) coming in better than the Street estimate of ($0.06). Revenue was $167.2 million, beating the Street estimate of $160.8 million.

The company expects Q1/23 revenue to be in the range of $175-180 million, better than the Street estimate of $163 million. For the full year, the company expects revenue to be in the range of $735-755 million, above the Street estimate of $727 million.

The company provided its 2025 expectations, calling for revenue of at least $1.2 billion and adjusted EBITDA of at least $100 million, both figures trending ahead of the Street estimates. The revenue outlook is consistent with management’s prior commentary of at least a 30% growth rate in the next several years.